Abstract
To map evidence on the use of digital technologies in the care of people with diabetes during the COVID-19 pandemic. This is a scoping review, based on the JBI manual, which included scientific articles and gray literature from nine primary and seven secondary databases. Articles were independently assessed by two reviewers. Rayyan® was used to select the studies. The description of study characterization is presented in a table and tables, ending in a narrative synthesis. A total of 1,964 studies were identified and, after selection, 23 publications remained for analysis. It turned out that telemedicine was used in all studies and remote consultation support technologies included continuous glucose monitoring devices, glucose data analysis software, insulin delivery systems, applications, audio and/or voice communication devices, which facilitated remote diabetes mellitus monitoring and management. Telehealth, monitoring technologies, insulin delivery systems and communication devices were tools used to monitor patients with diabetes during the pandemic.
Highlights
The COVID-19 pandemic imposed the need for new strategies and adaptations of health services to act in the face of the reality of social distancing
People with diabetes mellitus (DM) are at greater risk of developing complications when they have COVID-19, and on the other hand, SARS-CoV-2 could act as a diabetogenic agent as it is capable of causing direct damage to the pancreas, which can worsen hyperglycemia and even induce DM in individuals without the disease[3]
The articles were developed in Spain (n = 4), India (n = 3) and Brazil (n = 2), followed by studies published in the United States of America (USA), Singapore, United Kingdom, Israel, Italy, Australia, Colombia, Japan, Germany, France, Saudi Arabia, China, England and Greece, which published one article each
Summary
The COVID-19 pandemic imposed the need for new strategies and adaptations of health services to act in the face of the reality of social distancing. A study identified that most of the technologies implemented in the pandemic included healthcare providers and consumers, due to the extreme measures imposed to prevent the spread of COVID-19, interrupting the provision of health services for many patients, especially those with chronic conditions[2]. In this perspective, multiple countries sought to adopt innovations in health, with the aim of providing continuous care to clients with chronic conditions and at risk for COVID-19, such as patients with diabetes mellitus (DM). People with DM are at greater risk of developing complications when they have COVID-19, and on the other hand, SARS-CoV-2 could act as a diabetogenic agent as it is capable of causing direct damage to the pancreas, which can worsen hyperglycemia and even induce DM in individuals without the disease[3]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
